

Crenessity

Patient Inform	ation:			
Name:				
Member ID:				
Address:				
City, State, Zip:				
Date of Birth:				
	4.			
Prescriber Info	ormation:			
Name:				
NPI:				
Phone Number				
Fax Number				
Address:				
City, State, Zip:				
Requested Me	dication			
Rx Name:				
Rx Strength				
Rx Quantity:				
Rx Frequency:				
Rx Route of				
Administration:				
Diagnosis and I	CD Code:			
prescribed a medi quantities can be Upon receipt of SECTION A: requests. Pha medications t	cation for your provided. Plea the complete Please no armacy pri that are no	efit requires that we review certain requests for coverage with the pre- repatient that requires Prior Authorization before benefit coverage or cov- use complete the following questions then fax this form to the toll-free nu- d form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required or authorization reviews can be subject to trial with a total listed within the criteria. The policies are subject to	erage of a umber liste the plan for ALL idditiona change	idditional d below. 's rules.
on COMAR r	<u>equiremer</u>	ts, MDH transmittals and updates to treatment guide	elines.	
1 Is the	request an I	NITIAL or CONTINUATION of therapy?		
[] Initi	al (If checked	I, go to 7)		
[] Cor	ntinuation (If o	checked, go to 2)		

If you have any questions, call: 1-888-258-8250

Version 09.2025

2	Is the patient currently receiving the requested medication?	Yes	No
	[If no, skip to question 7.]		
3	Has the patient been receiving medication samples of the requested medication?	Yes	No
	[If yes, skip to question 7.]		
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan?	Yes	No
	[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]		
	[If no, skip to question 7.]		
5	Will the patient continue to receive concomitant glucocorticoid replacement (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)?	Yes	No
	[If no, no further questions.]		
6	Has the patient been taking the requested medication for AT LEAST 3 months and has experienced a clinically significant benefit from the medication, as documented by the prescriber? ACTION REQUIRED: Submit supporting documentation.	Yes	No
	[Note: Examples of responses to requested medication include reduced androstenedione levels, decreased 17-hydroxyprogesterone levels, or reduction in glucocorticoid dose from baseline (e.g., prior to Crenessity therapy) or improved or stabilized clinical signs/symptoms of classic Congenital Adrenal Hyperplasia (e.g., decrease in body mass index standard deviation scores, improved insulin resistance, reduction of hirsutism, or improvement in androstenedione-to-testosterone ratio).]		
	[No further questions.]		
7	What is the indication or diagnosis?		
	[] Classic congenital adrenal hyperplasia (CAH) (If checked, go to 8)		
	[] Other (If checked, no further questions)		
8	Is the patient 4 years of age or older?	Yes	No
	[If no, no further questions.]		

If you have any questions, call: 1-888-258-8250

9	Has documentation been submitted to confirm the patient has classic congenital adrenal hyperplasia (CAH) as evidenced by: A) Positive newborn screening with confirmatory second-tier testing, B) Pretreatment serum 17-hydroxyprogesterone (17-OHP) level greater than 3,000 ng/dL, C) Cosyntropin stimulation 17-OHP level greater than 10,000 ng/dL, or D) Genetic variant in <i>CYP21A2</i> gene? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
	[ii no, no futilier questions.]		
10	Has the patient been taking systemic glucocorticoids (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)? ACTION REQUIRED: Submit supporting documentation.	Yes	No
	[Note: Total glucocorticoid doses in hydrocortisone dose equivalents - patients 4 to 17 years of age require greater than 12 mg/m2/day or patients 18 years of age or older require greater than 13 mg/m2/day.]		
	[If no, no further questions.]		
11	Does the provider attest that the patient will continue to be treated with glucocorticoids in combination with the requested medication?	Yes	No
	[If no, no further questions.]		
10	Done the noticet have a history of hilatory I advantal atomy, by a pituitarion, or other	Vaa	No
12	Does the patient have a history of bilateral adrenalectomy, hypopituitarism, or other conditions requiring chronic therapy with oral glucocorticoids?	Yes	No
	[If yes, no further questions.]		
13	Does the patient have any evidence of chronic renal or liver disease?	Yes	No
	[If yes, no further questions.]		
14	Does the patient have a history of clinically concerning cardiac arrhythmia (including long QT syndrome or prolongation of QT interval)?	Yes	No
	[If yes, no further questions.]		
15	Is the requested medication prescribed by or in consultation with an endocrinologist and/or geneticist?	Yes	No
	[If no, no further questions.]		
16	Does the prescribed dosing exceed Food and Drug Administration (FDA) approved indication?	Yes	No
	[Dosing weight: 10 kg to less than 20 kg: 25 mg twice daily. Dosing weight: 20 kg		

If you have any questions, call: 1-888-258-8250



	to less than 55 kg: 50 mg twice daily. Dosing weight: greater than or equal to 55 kg: 100 mg twice daily.]		
Pl	ease document the diagnoses, symptoms, and/or any other information importan	nt to this i	review:
SEC	CTION B: <u>Physician Signature</u>		

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

PHYSICIAN SIGNATURE

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 09.2025

DATE